A Novel Anti-Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence
Completed · Early Phase 1 · Has a placebo group
Conditions studied: Cocaine Use Disorders
In brief
The research proposed in this application will determine the initial efficacy, safety and tolerability of a novel drug combination, bupropion and naltrexone, as a pharmacotherapy for cocaine dependence. A rigorous, inpatient human laboratory study will be conducted. The proposed study is innovative and important because it will provide the impetus for the conduct of double blind, placebo-controlled trials to further demonstrate the efficacy of bupropion-naltrexone combinations for managing cocaine dependence.
Key facts
- Study ID
- NCT01739192
- Run by
- Craig Rush
- People needed
- 34
- Starts
- 2013-01-01
- Expected to finish
- 2018-06-01
- Last updated by the study team
- 2018-06-26
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Recent cocaine use
You may not qualify if…
- Abnormal screening outcome (e.g., ECG, blood chemistry result) that study physicians deem clinically significant.
- Current or past histories of substance abuse or dependence that are deemed by the study physicians to interfere with study completion.
- History of serious physical disease, current physical disease, impaired cardiovascular functioning, chronic obstructive pulmonary disease, history of seizure or current or past histories of serious psychiatric disorder that in the opinion of the study physician would interfere with study participation will be excluded from participation.
- Females not currently using effective birth control.
- Contraindications to cocaine, bupropion or naltrexone,
Where it is running
- University of Kentucky Medical Center — Lexington, Kentucky, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.